期刊文献+

自组装白蛋白纳米粒的制备及体外释药行为 被引量:2

Fabrication of albumin nanoparticles through self-assembly and its in vitro release characteristics
下载PDF
导出
摘要 目的以紫杉醇为难溶性药物模型,制备自组装紫杉醇白蛋白纳米粒。方法谷胱甘肽作为还原剂,经细胞超声制备白蛋白纳米粒,通过正交试验筛选出最优处方。结果结果表明BSA浓度为1.5 g·L-1,谷胱甘肽用量为90 mg,紫杉醇/白蛋白质量比为1:20时,可以制备出表面圆整,粒径为91.19 nm,zeta电位-12.8 mv,包封率为90.8%,载药量为4.5%的紫杉醇白蛋白纳米粒,体外药物释放符合peppas模型,n=0.29,主要以扩散释药为主。结论自组装法制备出的白蛋白纳米粒粒径均一可控,并可显著提高白蛋白对难溶性药物的包封率。 Objective To fabricate albumin nanoparticles through self-assembly of BSA, using paclitaxel as a model drug. Methods Glutathione was applied as reducing agent to prepare albumin nanoparticles through ultrasonic cell disrupting, and orthogonal design was used to optimize the formulation. Results Spherical paclitaxel albumin nanoparticles were made with mean particle size 91.19 nm, Zeta potential-12.8 mv, drug entrapment efficiency 90.8% and drug loading 4.5%.The mechanism of release was drug diffusion from matrix by fitting drug release data with Peppas model. Conclusion Albumin-bound hydrophobic drug nanoparticles with controlled particle size and high encapsulation efficiency were obtained through self-assembly method.
出处 《中国药剂学杂志(网络版)》 2014年第4期17-24,共8页 Chinese Journal of Pharmaceutics:Online Edition
关键词 药剂学 白蛋白纳米粒 自组装 紫杉醇 粒径 pharmaceutics albumin nanoparticles self-assembly method paclitaxel particle diameter
  • 相关文献

参考文献11

  • 1王孝平,邢树礼.考马斯亮蓝法测定蛋白含量的研究[J].天津化工,2009,23(3):40-42. 被引量:300
  • 2张晓燕,平其能.多西紫杉醇白蛋白纳米粒的制备及体外评价[J].药学进展,2008,32(5):223-228. 被引量:23
  • 3张良珂,侯世祥,宋相容,卢懿.一种白蛋白纳米粒的制备与评价[J].中国药学杂志,2007,42(5):365-367. 被引量:15
  • 4Chetan Yewale,Dipesh Baradia,Imran Vhora,Ambikanandan Misra.Proteins: emerging carrier for delivery of cancer therapeutics[J].Expert Opinion on Drug Delivery.2013(10) 被引量:1
  • 5Liqun Jiang,Yisheng Xu,Qi Liu,Yue Tang,Liang Ge,Chunli Zheng,Jiabi Zhu,Jianping Liu.A nontoxic disulfide bond reducing method for lipophilic drug-loaded albumin nanoparticle preparation: Formation dynamics, influencing factors and formation mechanisms investigation[J].International Journal of Pharmaceutics (-).2013(1-2) 被引量:1
  • 6Ahu Yuan,Jinhui Wu,Chenchen Song,Xiaolei Tang,Qian Qiao,Lili Zhao,Guangming Gong,Yiqiao Hu.A novel self‐assembly albumin nanocarrier for reducing doxorubicin‐mediated cardiotoxicity[J].J Pharm Sci.2013(5) 被引量:1
  • 7Hai Wang,Ying Zhao,Yan Wu,Yu-lin Hu,Kaihui Nan,Guangjun Nie,Hao Chen.Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles[J].Biomaterials.2011(32) 被引量:1
  • 8Karsten Ulbrich,Martin Michaelis,Florian Rothweiler,Thomas Knobloch,Patchima Sithisarn,Jindrich Cinatl,J?rg Kreuter.Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells[J].International Journal of Pharmaceutics.2011(1) 被引量:1
  • 9Ji Yeon Jun,Hoang Hai Nguyen,Sae-Yeol-Rim Paik,Hyang Sook Chun,Byeong-Cheol Kang,Sanghoon Ko.Preparation of size-controlled bovine serum albumin (BSA) nanoparticles by a modified desolvation method[J].Food Chemistry.2011(4) 被引量:1
  • 10Hasan Kouchakzadeh,Seyed Abbas Shojaosadati,Amir Maghsoudi,Ebrahim Vasheghani Farahani.Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology[J].AAPS PharmSciTech.2010(3) 被引量:1

二级参考文献21

共引文献335

同被引文献55

  • 1张鲁明,赵秀杰.多肽蛋白药物制剂研究的几个热点[J].中国药师,2004,7(9):673-676. 被引量:1
  • 2章怡彬,梁文权,高建青.纳米粒作为抗肿瘤药物载体的研究进展[J].医药导报,2006,25(6):551-553. 被引量:6
  • 3黄健,高春生,梅兴国.多肽和蛋白类药物口服给药的可行性探讨[J].国际药学研究杂志,2007,34(4):298-300. 被引量:2
  • 4蒋刚彪,耿博文,方羽生,高永峰.聚合物胶束作为药物载体的应用[J].现代化工,2007,27(10):69-71. 被引量:3
  • 5Rao SV, Yajurvedi K,Shao J.Seif-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: Ⅲ. In vivo oral absorption study.lnt J Pharm. 2008;362(1-2): 16-19. 被引量:1
  • 6Lyons KC,Charman WN,MUler R,et al.Factors limiting the oral bioavailability of N-acetylglucosaminyI-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion.lnt J Pharm.2000; 199(1):17-28. 被引量:1
  • 7Toblo M,SSnchez A,Vila A,et al.The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration.Colloids Surf B Biointerfaces. 2000; 18(3-4):315-323. 被引量:1
  • 8Desai MP, Labhasetwar V, Amidon GL,et al.Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size. Pharm Res. 1996; 13( 12): 1838-1845. 被引量:1
  • 9纳米技术在新药研发中的应用.生命经纬.[2006-4-5].http://biox.cn/content/2006405/42830. 被引量:1
  • 10des Rieux A,Fievez V, Garinot M,et al.Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1-27. 被引量:1

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部